Andy Batts
Long only, value, growth, momentum

Cynosure: The Stock Is Cheap, The Story Is Compelling

The aesthetic devices market is seeing various technological advancements leading to high functionality, lower costs, and ease of operation. The emergence of minimally invasive and non-invasive aesthetic procedures is fueling the growth of this market. Cynosure (NASDAQ:CYNO), a leading player in this market, hasn't seen much activity in its stock in 2013. The stock has traded between a 52-week low of $21.09 and a 52-week high of $30.20. Currently it is trading around $26. The company's EPS is expected to rise more than 50% next year. Its recent acquisition of Palomar Medical Technologies is expected to result in $8 million to $10 million cost synergies in 2014. I feel that the stock is a good bargain at the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details